(3-Cyano-5-fluorophenyl)biaryl Negative Allosteric Modulators of mGlu5: Discovery of a New Tool Compound with Activity in the OSS Mouse Model of Addiction
Authors:
- Brittney S. BatesBBBrittney S. Bates
- Usha N. MenonUMUsha N. Menon
- Satyawan B. JadhavSJSatyawan B. Jadhav
- Alexander S. KaneAKAlexander S. Kane
- Alice L. RodriguezARAlice L. Rodriguez
- P. Jeffrey ConnPCP. Jeffrey Conn
- Christopher M. OlsenChristopher M. Olsen
- Danny G. WinderDWDanny G. Winder
- Kyle A. EmmitteKyle A. Emmitte
- 3 March 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (8) , 471-482
Abstract
Glutamate is the major excitatory transmitter in the mammalian central nervous system (CNS), exerting its effects through both ionotropic and metabotropic glutamate receptors. The metabotropic glutamate receptors (mGlus) belong to family C of the G-protein-coupled receptors (GPCRs). The eight mGlus identified to date are classified into three groups based on their structure, preferred signal transduction mechanisms, and pharmacology (group I: mGlu1 and mGlu5; group II: mGlu2 and mGlu3; group III: mGlu4, mGlu6, mGlu7, and mGlu8). Noncompetitive antagonists, also known as negative allosteric modulators (NAMs), of mGlu5 offer potential therapeutic applications in diseases such as pain, anxiety, gastresophageal reflux disease (GERD), Parkinson’s disease (PD), fragile X syndrome, and addiction. The development of structure−activity relationships (SAR) in a (3-cyano-5-fluorophenyl)biaryl series using our functional cell-based assay is described in this communication. Further characterization of a selected compound, 3-fluoro-5-(2-methylbenzo[d]thiazol-5-yl)benzonitrile, in additional cell based assays as well as in vitro assays designed to measure its metabolic stability and protein binding indicated its potential utility as an in vivo tool. Subsequent evaluation of the same compound in a pharmacokinetic study using intraperitoneal dosing in mice showed good exposure in both plasma and brain samples. The compound was efficacious in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu5 antagonists. A new operant model of addiction termed operant sensation seeking (OSS) was chosen as a second behavioral assay. The compound also proved efficacious in the OSS model and constitutes the first reported example of efficacy with a small molecule mGlu5 NAM in this novel assay.Keywords
This publication has 68 references indexed in Scilit:
- 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in ratsBioorganic & Medicinal Chemistry Letters, 2010
- Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTSBioorganic & Medicinal Chemistry Letters, 2009
- Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5Bioorganic & Medicinal Chemistry Letters, 2009
- Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seekingBehavioural Brain Research, 2009
- Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotypeBioorganic & Medicinal Chemistry Letters, 2009
- Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO miceNeurobiology of Disease, 2008
- Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffoldBioorganic & Medicinal Chemistry Letters, 2008
- Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpinePsychopharmacology, 2008
- Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonistsBioorganic & Medicinal Chemistry Letters, 2007
- Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEPNeuropharmacology, 2005